HE FIRST ANTIRETROVIRAL DRUG COMBINATION LICENSED FOR STR USE IN THE RUSSIAN FEDERATION
https://doi.org/10.22328/2077-9828-2014-6-3-78-85
Abstract
The results of STaR and SPIRIT trials of the STR antiretroviral drug combination RPV/FTC/TDF are discussed. STaR trial has convincingly demonstrated that the virological and immunological outcomes of two 2NRT+NNRTI ART regimens, RPV/FTC/TDF and EFV/FTC/TDF, which are administered by fixed STR doses, are equivalent. STR use of RPV/FTC/TDF was associated with decreases in the rates of ART discontinuation for adverse events, of detected CNS problems, and of skin rash development and with minimal changes in blood lipids. SPIRIP trial showed that, upon turning to STR RPV/FTC/TDF from a 2NRTI+PI/r regimen, ART effectiveness is preserved and lipid metabolism significantly improves. Based on these findings, STR using RPV/FTC/TDF is rated as a first-line therapy for HIV patients having baseline HIV RNA counts less that 105/mL, and also may be an option for simplification of ART and for correction and prevention of metabolic disorders associated with ART.
About the Authors
A. G. Rakhmanova
SaintPetersburg Center for Control of AIDS and Infectious Diseases
Russian Federation
Russian Federation
A. V. Kravchenko
Central Research Institute of Epidemiology
Russian Federation
Russian Federation
References
1. ParientiJ.J., BangsbergD.R., Verdon R., Gardner E.M. Better adherence with once-daily antiretroviral regimens: a meta-analysis // Clin Infect Dis.-2009.- Vol. 48 (4).- Р. 484-488.
2. Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 7.02; June, 2014) / European AIDS Clinical Society.- Р. 82.- URL: (http://eacsociety.org/Portals/0/140601_EACS%20EN7.02.pdf).
3. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents //Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) May 1, 2014 (http://AIDSinfo.nih.gov).
4. MollanK.R., SmurzynskiM., EronJJ., DaarE.S., Campbell T.B., SaxP.E., GulickR.M., Na.L, O'Keefe L., RobertsonK.R., Tierney. Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide: An Analysis of Trial Data // Annals of Internal Medicine.- Vol. 161 (1).- Р 1 - 10.
5. Cohen C., Andrade-Villanueva J., Clotet B., Fourie J., Johnson M.A., Ruxrungtham K., Wu H., Zorrilla C., Crauwels H., Rimsky L.T., Vanveggel S., Boven K. THRIVE study group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial // Lancet.- 2011.- Vol. 378.- P. 229-237. doi: 10.1016/S0140 - 6736(11)60983-5.
6. Molina J-M., CahnP., GrinsztejnB., LazzarinA., Mills A., Saag M., Supparatpinyo K., Walmsley S., Crauwels H., Rimsky L.T., Vanveggel S., BovenK. ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial // Lancet.- 2011.- Vol. 378.- P. 238 - 246. (doi: 10.1016/S0140-6736(11)60936-7).
7. Кравченко А.В., Канестри В.Г. Опыт применения препарата рилпивирин в схемах антиретровирусной терапии больных ВИЧ-инфекцией в России // Инфекционные болезни, 2013.- Т. 11, № 3.- С. 55-60.
8. Cohen C., WohlD., ArribasJ., Henry K., van LunzenJ., BlochM., Towner W., Wilkins E., EbrahimiR., Porter D., White K., Walker I., Chuck, S., De-Oertel S., Fralich T. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults // AIDS.- 2014.- Vol. 28 (7).- Р 989-997.
9. Cohen C., Wohl D., Arribas J., Henry K., van Lunzen J., Bloch M., Towner W., Wilkins E., Ebrahimi R., Porter D., Patel K., De-Oertel S., Fralich T., Guyer B. STaR Study: Single Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Maintains Non-Inferiority to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naive Adults through Week 96// 14th European AIDS Conference, October 16-19, 2013, Brussels, Belgium.- Abstr. LBPE7/17 www.EACS-CONFERENCE2013.COM
10. AiroldiM., ZaccarelliM., BisiL., Bini Т., AntinoriA., Mussini C., BaiF., Orofino G., SighinolfiL., GoriA., SuterF., MaggioloF. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects // Patient Prefer Adherence.- 2010.- Vol. 4.- Р. 115-125.
11. Palella Jr F.J., Fisher M., TebasP., Gazzard B., Ruane P., Van LunzenJ., Shamblaw D., FlammJ., EbrahimiR., Porter D., White K., HindmanJ., Elbert E., De-Oertel S., Fralich T. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants // AIDS.- 2014.- Vol. 28, № 3.- Р. 335-344.
12. SanfordM. Rilpivirine // Drugs.- 2012.- Vol. 73 (4).- P. 525 - 541.
Review
For citations:
Rakhmanova A.G., Kravchenko A.V. HE FIRST ANTIRETROVIRAL DRUG COMBINATION LICENSED FOR STR USE IN THE RUSSIAN FEDERATION. HIV Infection and Immunosuppressive Disorders. 2014;6(3):78-85. (In Russ.) https://doi.org/10.22328/2077-9828-2014-6-3-78-85
Views:
753
.png)
Email this article 